Thermo Fisher Scientific has announced an agreement to acquire Sanofi’s sterile fill-finish and packaging facility in Ridgefield, New Jersey, as part of a wider strategic partnership to strengthen drug product manufacturing in the United States. Financial details of the transaction remain undisclosed.

The acquisition will see Thermo Fisher continue production of Sanofi’s therapeutic portfolio at the site, while also addressing growing demand for sterile fill-finish and packaging services across the US pharmaceutical market. Over 200 employees currently at the Ridgefield site are expected to transition to Thermo Fisher once the deal is finalised in the second half of 2025.

Marc Casper, CEO of Thermo Fisher Scientific, said, “The Ridgefield facility will bolster our US manufacturing capabilities, allowing us to better serve our pharmaceutical and biotech clients with essential capacity for critical medicines.” He added that Thermo Fisher plans to invest further in the site’s capabilities and infrastructure.

Sanofi, headquartered in Paris, stated that the divestment aligns with its commitment to maintain reliable product supply while strengthening its presence in the US manufacturing landscape. The enhanced partnership with Thermo Fisher also supports future growth and development of the Ridgefield facility.

The Ridgefield site will be integrated into Thermo Fisher’s pharma services business, part of its Laboratory Products and Biopharma Services division. It complements the company’s existing sterile fill-finish operations in Greenville, North Carolina, and Plainville, Massachusetts—both of which form part of Thermo Fisher’s Accelerator platform for CDMO/CRO services catering to emerging biopharma clients.

Thermo Fisher is also upgrading its Greenville facility, shifting from traditional batch manufacturing to continuous production methods, reflecting broader industry moves towards advanced manufacturing technologies amid global uncertainty.